In the treatment of ovarian cancer, the high affinity and low affinity receptor types of FCGR3A may contribute to clinical outcomes in ovarian cancer treatment (Wang et al., 2017, 125). This evidence concerns the gene FCGR3A and ovarian carcinoma.